Zimmer Biomet Holdings, Inc. (ZBH) Stock 2026 Review

Zimmer Biomet, with a market capitalization of $17.18 billion, has an earnings yield of 9.6%, significantly higher than the industry average of 2.6%. The company has consistently exceeded earnings expectations over the past four quarters.

Analysts project an average 1-year price target of $100.85 for ZBH, with estimates ranging from a low of $83.83 to a high of $135.57. This reflects a positive outlook despite recent performance.

The current dividend yield for Zimmer Biomet Holdings, Inc. is 1.06%. This yield can be an attractive feature for income-focused investors.

Zimmer Biomet has experienced a 1-year return of -3.14%. While this indicates a decline, analysts remain optimistic about the company's future potential.

Over the last five years, Zimmer Biomet has seen a significant decline with a return of -41.15%. This long-term performance may concern some investors, but analysts still highlight its value stock status.

Zimmer Biomet is regarded as a value stock due to its attractive earnings yield of 9.6%, which outperforms the industry average. This aspect, along with its positive analyst ratings, makes it a noteworthy investment option.

Zimmer Biomet Holdings, Inc. has a market capitalization of $17.18 billion. This figure indicates the company's size and its position within the healthcare sector.